Collegium Pharmaceutical, Inc. (COLL)
24.69
+0.48
(+1.98%)
USD |
NASDAQ |
Nov 09, 10:23
Collegium Pharmaceutical Enterprise Value : 1.795B for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 1.795B |
| November 05, 2026 | 1.825B |
| November 04, 2026 | 1.778B |
| November 03, 2026 | 1.780B |
| November 02, 2026 | 1.779B |
| October 30, 2026 | 1.782B |
| October 29, 2026 | 1.790B |
| October 28, 2026 | 1.765B |
| October 27, 2026 | 1.758B |
| October 26, 2026 | 1.764B |
| October 23, 2026 | 1.756B |
| October 22, 2026 | 1.773B |
| October 21, 2026 | 1.755B |
| October 20, 2026 | 1.765B |
| October 19, 2026 | 1.758B |
| October 16, 2026 | 1.764B |
| October 15, 2026 | 1.763B |
| October 14, 2026 | 1.742B |
| October 13, 2026 | 1.712B |
| October 12, 2026 | 1.728B |
| October 09, 2026 | 1.729B |
| October 08, 2026 | 1.730B |
| October 07, 2026 | 1.724B |
| October 06, 2026 | 1.723B |
| October 05, 2026 | 1.723B |
| Date | Value |
|---|---|
| October 02, 2026 | 1.727B |
| October 01, 2026 | 1.722B |
| September 30, 2026 | 1.721B |
| September 29, 2026 | 1.791B |
| September 28, 2026 | 1.804B |
| September 25, 2026 | 1.801B |
| September 24, 2026 | 1.804B |
| September 23, 2026 | 1.798B |
| September 22, 2026 | 1.809B |
| September 21, 2026 | 1.817B |
| September 18, 2026 | 1.809B |
| September 17, 2026 | 1.796B |
| September 16, 2026 | 1.790B |
| September 15, 2026 | 1.778B |
| September 14, 2026 | 1.810B |
| September 11, 2026 | 1.808B |
| September 10, 2026 | 1.813B |
| September 09, 2026 | 1.828B |
| September 08, 2026 | 1.828B |
| September 04, 2026 | 1.833B |
| September 03, 2026 | 1.839B |
| September 02, 2026 | 1.858B |
| September 01, 2026 | 1.849B |
| August 31, 2026 | 1.868B |
| August 28, 2026 | 1.892B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.715B |
| Corcept Therapeutics, Inc. | 7.597B |
| Veru, Inc. | 13.04M |
| Johnson & Johnson | 692.32B |
| Eli Lilly & Co. | 1.319T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 21.76M |
| Revenue (Quarterly) | 216.34M |
| Total Expenses (Quarterly) | 194.58M |
| EPS Diluted (Quarterly) | 0.5956 |
| Gross Profit Margin (Quarterly) | 57.97% |
| Profit Margin (Quarterly) | 10.06% |
| Earnings Yield | 4.02% |
| Operating Earnings Yield | 13.43% |
| Normalized Earnings Yield | 5.299 |